An antitrust safe harbour for cross-company combination trials and data pooling
Companies say competition law stops them coordinating on combination trials and sharing failure data. A clear legal safe harbour for defined pro-patient collaborations would remove that excuse.
Competition authorities issue guidance or a block exemption, as the EU has for research and development agreements and as the US did for certain healthcare collaborations, that explicitly protects defined oncology collaborations: joint combination trials, sharing of safety and negative-efficacy data, pooled control arms, pre-competitive target validation and standard combination agreements, subject to transparency conditions (registration of the collaboration, publication of results). Companies frequently cite antitrust uncertainty as a reason not to share data or coordinate trials; whether that is a real barrier or a convenient one, a safe harbour removes it and lets other collaboration proposals proceed.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
Pages like this
not linked directly; found by shared links- IdeaA regulator-endorsed standard contract for inter-company combination trials
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
- IdeaUniversity licences with royalties indexed to benefit and global access
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.
- IdeaA public registry of stalled academic assets and shelved company compounds
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaA shared library of pooled control arms to shrink and speed future trials
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaPatient-held portable consent for reusing samples and data across studies
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaA federated learning consortium of cancer centres that jointly own the models
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaA commons for leftover trial biospecimens with standard access for approved research
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaA permanent neutral non-profit sponsor for multi-company platform trials
Shares An oncology patent pool for combination trials across companies, Secrecy and intellectual property block collaboration.